Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
- Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access
- 79% secondary patency at 12 months in complex patient populations supported by low reintervention burden (1.3 patency‑related reintervention rate per patient year) and a 3% clinically relevant access related infection rate
- CE mark approval enables Xeltis to commercialize aXess™ in Europe
EINDHOVEN, The Netherlands – 21 April, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announced new 12‑month clinical data from the aXess multi-center EU pivotal trial, which enrolled 120 patients in 22 clinical trial sites from 9 European countries, demonstrating the transformative potential of aXess™ in hemodialysis treatment.
